Biosimilars Insulin Market to Generate Substantial Increment in Dollar Opportunities Through 2016 - 2024

19/mar/2020 13:40:19 persistencemarketresearch Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder.

Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States.

In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called “Insulin glargine” and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe.

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @

Basaglar is the first “biosimilar” insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.

Biosimilar insulin proved to have an effective treatment for patients suffering from diabetes mellitus by reducing the cost for the treatment. There are some companies who have developed devices which allow the safe and less painful delivery of biosimilar insulin thus making the device a market differentiator even though it’s chemically equivalent to the branded product.

Many companies in the emerging economies have started developing biosimilar insulin due to the favorable regulatory requirements  as compared to the companies in developed countries where their stringent regulatory requirements. As the regulatory requirements for the approval process of biosimilars are considerably higher than those required for the generic drugs and entail the comprehensive analysis for each of its characteristics.

Biosimilars have increased the opportunities in healthcare services and have decreased the expenditures creating a significant competition between the companies manufacturing branded products and biosimilars. Globally, the major factors responsible for surging the demand for biosimilars insulin in the market are increase in diagnosed and undiagnosed diabetes, patent expiry for insulin, growing population.

Diabetes is considered to be one of the fastest growing disease and attribute to 3 million deaths annually, and has become a pandemic. Increasing poverty level in developing countries has created a pressure on the healthcare industry to develop cost effective products and treatment options especially for diabetes patients.

Access Full TOC of This Report @

The only aspects which can affect the biosimilars market are safety and efficacy of new biosimilars also the stringent regulatory bodies leading to delayed approvals.

According to the Biosimilars Pipeline Database, there are total 1,357 product entries for biobetters and biosimilars constitute 737 of them (March, 2016). Among the top targeted reference products, insulin and analogs constitute 51 and the companies producing it include Biocon, Mylan N.V., Sanofi, Novo Nordisk and others.

Sanofi, a multinational pharmaceutical company is also developing LixiLan, a mix of basal insulin with GLP-1 which is directed to treat for type 2 diabetes. Eli Lilly and Company, a U.S. based company is currently running Phase III clinical trials for a non-insulin drug Empagliflozin (BI10773) targeting the treatment for type 1 diabetes.

The new trend in the market is developing ultra-rapid acting insulins to replace Humalog and Novolog (patents expired) which is important for pump users and disorder related to real-time artificial pancreas. There are new attempts made by companies to create oral insulin such as ingestible capsules for better drug delivery.

Most of the biosimilars have reached Phase III and are soon to get approved by the respective regulatory bodies and will reach the market with cheaper prices as compared to the branded products. Various multinationals are forming alliances and partnerships to develop biosimilar insulin such as Eli Lilly and Company and Boehringer Ingelheim Gmb, Biocon Limited and Pfizer Inc., Mylan N.V. and  Momenta Pharmaceuticals.

For In-Depth Competitive Analysis, Buy Now @

The report covers exhaustive analysis on:

  • Biosimilars Insulin Market Segments
  • Biosimilars Insulin Market Dynamics
  • Biosimilars Insulin Market Size, 2016 – 2024
  • Biosimilars Insulin Market Size & Forecast 2016 to 2024
  • Biosimilars Insulin Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Biosimilars Insulin Market Drivers and Restraints

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

More About the Report –

Unprecedented access to a world of information has given rise to the empowered, albeit distrustful, consumer. So is the case with healthcare, where the patient has been rendered more informed and conscientious thanks to the extraordinary penetration of the Internet. The discerning patient now demands more affordable, sophisticated, transparent, and personalized healthcare services, creating the need for new models for care.

The advent of health information technology (HIT) components such as electronic health records (EHR), hospital information systems (HIS), picture archiving and communication systems (PACS), and vendor-neutral archives (VNA) has had just as transformational an impact on the overall healthcare sector as the concerns regarding security and privacy. Data theft, undue access to personal health records, and cyber-attacks are very real threats that the healthcare sector faces today.

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Animal Healthcare Market –

According to a report published by Persistence Market Research (PMR), the global animal healthcare market is expected to witness a CAGR of 4.8% from 2017 to 2025. In 2017, the market was worth US$ 30,744.2 Mn and is estimated to rise to a valuation of US$ 44,847.2 Mn by the end of 2025.

Dental Implants Market –

According to a new market report published by Persistence Market Research “Global Market Study on Dental Implants – Asia Pacific to Witness Fastest Growth by 2020,” the global Dental implants market was valued at USD 4,508.9 million in 2014 and is expected to grow at a CAGR of 9.7% from 2014 to 2020, to reach an estimated value of USD 7,879.5 million in 2020.

Globally, rising aging population has increases the demand for dental implants in the market. As a result, the market is expected to grow at a CAGR of about 9.7% from 2014 – 2020.

Bioinformatics Market –

According to a new market report published by Persistence Market Research “Global Market Study on Bioinformatics – Asia to Witness Fastest Growth by 2020,” the global bioinformatics market was valued at USD 4,110.6 million in 2014 and is expected to grow at a CAGR of 20.4% from 2014 to 2020, to reach an estimated value of USD 12,542.4 million in 2020.

Globally, rising R&D expenditures and a rising number of research activities have increased the demand for bioinformatics in the market. As a result, the market is expected to grow at a CAGR of about 20.4% from 2014 – 2020.

Hospital Beds Market – 

According to a new market report published by Persistence Market Research “Global Market Study on Hospital Beds: Asia to Witness Highest Growth by 2020”, the global hospital beds market was valued at USD 5,254.2 million in 2014 and is expected to expand at a CAGR of 4.2% from 2014 to 2020, to reach an estimated value of USD 6,731.8 million by 2020.

Cleanroom Technology Market –

According to a new market report published by Persistence Market Research titled Global Market Study on  Cleanroom Technology : Consumables to Witness Highest Growth by 2020, the global  cleanroom technology market  was valued at USD 3,156.0 million in 2014 and is expected to grow at a CAGR of 5.2 % from 2014 to 2020 to reach an estimated value of USD 4,290.1 ​​million by 2020.

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR's collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

305 Broadway, 7th Floor
New York City, NY 10007
United States + 1-646-568-7751
E-mail id-


blog comments powered by Disqus è un servizio offerto da Factotum Srl